These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 16376743

  • 1. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.
    Matulonis UA, Seiden MV, Roche M, Krasner C, Fuller AF, Atkinson T, Kornblith A, Penson R.
    J Pain Symptom Manage; 2005 Dec; 30(6):563-9. PubMed ID: 16376743
    [Abstract] [Full Text] [Related]

  • 2. Octreotide in the management of bowel obstruction in terminal ovarian cancer.
    Mangili G, Franchi M, Mariani A, Zanaboni F, Rabaiotti E, Frigerio L, Bolis PF, Ferrari A.
    Gynecol Oncol; 1996 Jun; 61(3):345-8. PubMed ID: 8641613
    [Abstract] [Full Text] [Related]

  • 3. Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction.
    Shima Y, Ohtsu A, Shirao K, Sasaki Y.
    Jpn J Clin Oncol; 2008 May; 38(5):354-9. PubMed ID: 18490369
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of depot long-acting release octreotide therapy in severe dumping syndrome.
    Penning C, Vecht J, Masclee AA.
    Aliment Pharmacol Ther; 2005 Nov 15; 22(10):963-9. PubMed ID: 16268971
    [Abstract] [Full Text] [Related]

  • 5. Sustained release octreotide may have a role in the treatment of malignant bowel obstruction.
    Massacesi C, Galeazzi G.
    Palliat Med; 2006 Oct 15; 20(7):715-6. PubMed ID: 17060271
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.
    Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW, Wong WM, Wong BC.
    Hepatology; 2002 Sep 15; 36(3):687-91. PubMed ID: 12198662
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of the long-acting repeatable formulation of the somatostatin analogue octreotide in postoperative dumping.
    Arts J, Caenepeel P, Bisschops R, Dewulf D, Holvoet L, Piessevaux H, Bourgeois S, Sifrim D, Janssens J, Tack J.
    Clin Gastroenterol Hepatol; 2009 Apr 15; 7(4):432-7. PubMed ID: 19264574
    [Abstract] [Full Text] [Related]

  • 9. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients.
    Nikou GC, Toumpanakis C, Katsiari C, Charalambopoulos D, Sfikakis PP.
    J Clin Rheumatol; 2007 Jun 15; 13(3):119-23. PubMed ID: 17551375
    [Abstract] [Full Text] [Related]

  • 10. A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer.
    Chi DS, Phaëton R, Miner TJ, Kardos SV, Diaz JP, Leitao MM, Gardner G, Huh J, Tew WP, Konner JA, Sonoda Y, Abu-Rustum NR, Barakat RR, Jaques DP.
    Oncologist; 2009 Aug 15; 14(8):835-9. PubMed ID: 19684071
    [Abstract] [Full Text] [Related]

  • 11. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
    Toumpanakis C, Garland J, Marelli L, Srirajaskanthan R, Soh J, Davies P, Buscombe J, Caplin ME.
    Aliment Pharmacol Ther; 2009 Oct 15; 30(7):733-40. PubMed ID: 19573169
    [Abstract] [Full Text] [Related]

  • 12. An open trial of octreotide long-acting release in the management of short bowel syndrome.
    Nehra V, Camilleri M, Burton D, Oenning L, Kelly DG.
    Am J Gastroenterol; 2001 May 15; 96(5):1494-8. PubMed ID: 11374688
    [Abstract] [Full Text] [Related]

  • 13. Octreotide long-acting formulation (LAR) in chronic loperamide-refractory diarrhea not related to cancer treatment.
    Mystakidou K, Katsouda E, Tsilika E, Smyrniotis V, Vassiliou I, Tsiatas M, Vlahos L.
    Anticancer Res; 2006 May 15; 26(3B):2325-8. PubMed ID: 16821610
    [Abstract] [Full Text] [Related]

  • 14. SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction.
    Laval G, Rousselot H, Toussaint-Martel S, Mayer F, Terrebonne E, François E, Brixi H, Nguyen T, Bourdeix I, Bisot-Locard S, Zelek L, SALTO Study Group.
    Bull Cancer; 2012 Feb 01; 99(2):E1-9. PubMed ID: 22265994
    [Abstract] [Full Text] [Related]

  • 15. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors.
    Chadha MK, Lombardo J, Mashtare T, Wilding GE, Litwin A, Raczyk C, Gibbs JF, Kuvshinoff B, Javle MM, Iyer RV.
    Anticancer Res; 2009 Oct 01; 29(10):4127-30. PubMed ID: 19846960
    [Abstract] [Full Text] [Related]

  • 16. Effect of long-term treatment with octreotide on rectal sensitivity in patients with non-constipated irritable bowel syndrome.
    Klooker TK, Kuiken SD, Lei A, Boeckxstaens GE.
    Aliment Pharmacol Ther; 2007 Aug 15; 26(4):605-15. PubMed ID: 17661764
    [Abstract] [Full Text] [Related]

  • 17. Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer.
    Jatoi A, Podratz KC, Gill P, Hartmann LC.
    J Support Oncol; 2004 Aug 15; 2(4):323-34; discussion 334-7. PubMed ID: 15357517
    [Abstract] [Full Text] [Related]

  • 18. Octreotide for malignant bowel obstruction: twenty years after.
    Mercadante S, Porzio G.
    Crit Rev Oncol Hematol; 2012 Sep 15; 83(3):388-92. PubMed ID: 22277783
    [Abstract] [Full Text] [Related]

  • 19. Aggressive pharmacological treatment for reversing malignant bowel obstruction.
    Mercadante S, Ferrera P, Villari P, Marrazzo A.
    J Pain Symptom Manage; 2004 Oct 15; 28(4):412-6. PubMed ID: 15471659
    [Abstract] [Full Text] [Related]

  • 20. Successful use of long-acting octreotide for intractable chronic gastrointestinal bleeding in children.
    O'Meara M, Cicalese MP, Bordugo A, Ambrosi A, Hadzic N, Mieli-Vergani G.
    J Pediatr Gastroenterol Nutr; 2015 Jan 15; 60(1):48-53. PubMed ID: 25162361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.